Acumen posts presentation on ACU193 Phase 1 trial design for early Alzheimer's disease

Acumen Pharmaceuticals, Inc.

ACU193 is a monoclonal antibody that selectively targets toxic amyloid-beta oligomers for early Alzheimer's disease.
The Phase 1 INTERCEPT-AD trial design is detailed in the presentation posted on November 10, 2021.
The presentation is available on Acumen's website and was furnished to the SEC as Exhibit 99.1.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.